Recrutamento encerrado
FASE
Número Europeu 2019-002463-10
BO42864 AcceleRET-Lung
A Phase III, Randomized, Open-Label Study of Pralsetinib Versus Standard of Care for First-Line Treatment of RET Fusion-Positive, Metastatic Non-Small Cell Lung Cancer
Detalhes
Destaques